| PIK3CA mutations and copy number gains in human lung cancers H Yamamoto, H Shigematsu, M Nomura, WW Lockwood, M Sato, ... Cancer research 68 (17), 6913-6921, 2008 | 564 | 2008 |
| Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins WW Lockwood, K Zejnullahu, JE Bradner, H Varmus Proceedings of the National Academy of Sciences 109 (47), 19408-19413, 2012 | 403 | 2012 |
| Lung cancer cell lines as tools for biomedical discovery and research AF Gazdar, L Girard, WW Lockwood, WL Lam, JD Minna Journal of the National Cancer Institute 102 (17), 1310-1321, 2010 | 299 | 2010 |
| Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance JKM Lim, A Delaidelli, SW Minaker, HF Zhang, M Colovic, H Yang, ... Proceedings of the National Academy of Sciences 116 (19), 9433-9442, 2019 | 277 | 2019 |
| Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells J Soh, N Okumura, WW Lockwood, H Yamamoto, H Shigematsu, ... PloS one 4 (10), e7464, 2009 | 274 | 2009 |
| Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines J Gandhi, J Zhang, Y Xie, J Soh, H Shigematsu, W Zhang, H Yamamoto, ... PloS one 4 (2), e4576, 2009 | 238 | 2009 |
| Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis EA Marshall, KW Ng, SHY Kung, EM Conway, VD Martinez, EC Halvorsen, ... Molecular cancer 15, 1-15, 2016 | 215 | 2016 |
| TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer DT Starczynowski, WW Lockwood, S Deléhouzée, R Chari, J Wegrzyn, ... The Journal of clinical investigation 121 (10), 4095-4105, 2011 | 201 | 2011 |
| Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers A Drilon, R Somwar, BP Mangatt, H Edgren, P Desmeules, A Ruusulehto, ... Cancer discovery 8 (6), 686-695, 2018 | 190 | 2018 |
| Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma AM Unni, WW Lockwood, K Zejnullahu, SQ Lee-Lin, H Varmus Elife 4, e06907, 2015 | 189 | 2015 |
| SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer Y Xue, B Meehan, Z Fu, XQD Wang, PO Fiset, R Rieker, C Levins, T Kong, ... Nature communications 10 (1), 557, 2019 | 181 | 2019 |
| Lung cancer signatures in plasma based on proteome profiling of mouse tumor models A Taguchi, K Politi, SJ Pitteri, WW Lockwood, VM Faça, K Kelly-Spratt, ... Cancer cell 20 (3), 289-299, 2011 | 180 | 2011 |
| Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines R Somwar, H Erdjument-Bromage, E Larsson, D Shum, WW Lockwood, ... Proceedings of the National Academy of Sciences 108 (39), 16375-16380, 2011 | 172 | 2011 |
| MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors T Kubo, H Yamamoto, WW Lockwood, I Valencia, J Soh, M Peyton, M Jida, ... International journal of cancer 124 (8), 1778-1784, 2009 | 161 | 2009 |
| Recent advances in array comparative genomic hybridization technologies and their applications in human genetics WW Lockwood, R Chari, B Chi, WL Lam European Journal of Human Genetics 14 (2), 139-148, 2006 | 161 | 2006 |
| High resolution analysis of non‐small cell lung cancer cell lines by whole genome tiling path array CGH C Garnis, WW Lockwood, E Vucic, Y Ge, L Girard, JD Minna, AF Gazdar, ... International Journal of Cancer 118 (6), 1556-1564, 2006 | 159 | 2006 |
| DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers WW Lockwood, R Chari, BP Coe, L Girard, C Macaulay, S Lam, ... Oncogene 27 (33), 4615-4624, 2008 | 146 | 2008 |
| Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma WW Lockwood, R Chari, BP Coe, KL Thu, C Garnis, CA Malloff, ... PLoS medicine 7 (7), e1000315, 2010 | 133 | 2010 |
| Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer K Suzawa, M Offin, D Lu, C Kurzatkowski, M Vojnic, RS Smith, JK Sabari, ... Clinical Cancer Research 25 (4), 1248-1260, 2019 | 125 | 2019 |
| Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma L Lin, AJ Bass, WW Lockwood, Z Wang, AL Silvers, DG Thomas, ... Proceedings of the National Academy of Sciences 109 (11), 4251-4256, 2012 | 103 | 2012 |
Wan L. LamBC Cancer Research Centre; University of British ColumbiaVerified email at bccrc.ca
